RELX Stock Analysis: Relx | NYSE
Specialty Business Services | NYSE, USA | Market Cap: 62.781m USD | 12M Return: -16.4% | US7595301083 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 64.3M
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
RELX PLC is a London-headquartered information analytics company that provides data-driven decision tools and professional information services to business customers across North America, Europe, and other international markets. The company operates through four business segments: Risk (analytics and predictive tools, including commercial healthcare products), Scientific, Technical & Medical (research and healthcare data), Legal (regulatory and business information), and Exhibitions (in-person and online events and marketplaces). Originally incorporated in 1903 and formerly known as Reed Elsevier PLC, RELX serves professional and institutional clients with subscription-based information products across multiple industries.
The business model is characteristic of the professional information services sector, where revenue is typically generated through recurring subscriptions, licensing fees, and long-term institutional contracts rather than consumer-facing transactions. RELXs diversified portfolio across legal, scientific, risk analytics, and events gives it exposure to relatively defensive end markets such as legal research, healthcare, and insurance underwriting.
- Risk segment analytics revenue accelerates on insurance and banking demand
- Scientific Technical Medical data subscriptions drive recurring revenue growth
- Exhibitions segment rebounds as in-person event attendance and ticket sales normalize
- Legal regulatory information pricing offsets print decline with digital migration
- US healthcare commercial products expand margins within Risk segment
| Net Income: 2.26b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA -0.03 > 1.0 |
| NWC/Revenue: -36.85% < 20% (prev -31.89%; Δ -4.97% < -1%) |
| CFO/TA 0.19 > 3% & CFO 2.92b > Net Income 2.26b |
| Net Debt (8.78b) to EBITDA (3.89b): 2.26 < 3 |
| Current Ratio: 0.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.79b) vs 12m ago -5.71% < -2% |
| Gross Margin: 62.65% > 18% (prev 64.15%; Δ -1.50% > 0.5%) |
| Asset Turnover: 66.22% > 50% (prev 66.55%; Δ -0.34% > 0%) |
| Interest Coverage Ratio: 16.67 > 6 (EBIT TTM 3.13b / Interest Expense TTM 188.0m) |
| DSRI: 1.06 (Receivables 2.34b/2.16b, Revenue 9.72b/9.53b) |
| GMI: 1.02 (GM 64.15% / 62.65%) |
| AQI: 0.99 (AQ_t 0.79 / AQ_t-1 0.80) |
| SGI: 1.02 (Revenue 9.72b / 9.53b) |
| TATA: -0.04 (NI 2.26b - CFO 2.92b) / TA 15.0b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of October 14, 2026, the stock is trading at USD 36.70 with a total of 1,602,093 shares traded. Over the past week, the price has changed by +7.85%, over one month by +2.74%, over three months by +10.68% and over the past year by -16.43%.
Current recommended Stop Loss: 34.80 (which is 5.2% or 2.5 ATR below the current price).
Relx has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy RELX.
- StrongBuy: 3
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 53.4 | 45.4% |
Market Cap GBP = 47.5b (62.8b USD * 0.75717 USD.GBP)
P/E Trailing = 21.6347
P/E Forward = 15.0602
P/S = 6.4589
P/B = 34.5927
P/EG = 1.1589
Revenue TTM = 9.72b GBP
EBIT TTM = 3.13b GBP
EBITDA TTM = 3.89b GBP
Long Term Debt = 5.63b GBP (from longTermDebt, last fiscal year)
Short Term Debt = 2.34b GBP (from shortTermDebt, last quarter)
Debt = 9.00b GBP (from shortLongTermDebtTotal, last quarter) + Leases 97.0m
Net Debt = 8.78b GBP (calculated: Debt 9.00b - CCE 220.0m)
Enterprise Value = 56.3b GBP (47.5b + Debt 9.00b - CCE 220.0m)
Interest Coverage Ratio = 16.67 (Ebit TTM 3.13b / Interest Expense TTM 188.0m)
EV/FCF = 19.39x (Enterprise Value 56.3b / FCF TTM 2.90b)
FCF Yield = 5.16% (FCF TTM 2.90b / Enterprise Value 56.3b)
FCF Margin = 29.88% (FCF TTM 2.90b / Revenue TTM 9.72b)
Net Margin = 23.27% (Net Income TTM 2.26b / Revenue TTM 9.72b)
Gross Margin = 62.65% ((Revenue TTM 9.72b - Cost of Revenue TTM 3.63b) / Revenue TTM)
Gross Margin QoQ = 64.09% (prev 61.21%)
Tobins Q-Ratio = 3.75 (Enterprise Value 56.3b / Total Assets 15.0b)
Interest Expense / Debt = 2.09% (Interest Expense 188.0m / Debt 9.00b)
Taxrate = 23.95% (716.0m / 2.99b)
NOPAT = 2.38b (EBIT 3.13b * (1 - 23.95%))
Current Ratio = 0.45 (Total Current Assets 2.92b / Total Current Liabilities 6.50b)
Debt / Equity = 7.27 (Debt 9.00b / totalStockholderEquity, last quarter 1.24b)
Debt / EBITDA = 2.26 (Net Debt 8.78b / EBITDA 3.89b)
Debt / FCF = 3.02 (Net Debt 8.78b / FCF TTM 2.90b)
Total Stockholder Equity = 2.32b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.41% (Net Income 2.26b / Total Assets 15.0b)
RoE = 97.66% (Net Income TTM 2.26b / Total Stockholder Equity 2.32b)
RoCE = 39.44% (EBIT 3.13b / Capital Employed (Equity 2.32b + L.T.Debt 5.63b))
RoIC = 22.36% (NOPAT 2.38b / Invested Capital 10.7b)
WACC = 5.31% (E(47.5b)/V(56.5b) * Re(6.01%) + D(9.00b)/V(56.5b) * Rd(2.09%) * (1-Tc(0.24)))
Discount Rate = 6.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.14 | Cagr: -3.18%
[DCF] Terminal Value 76.05% ; FCFF base≈2.85b ; Y1≈2.98b ; Y5≈3.41b
[DCF] Fair Price = 25.19 (EV 52.6b - Net Debt 8.78b = Equity 43.8b / Shares 1.74b; r=8.35% [WACC [floored]]; 5y FCF grow 4.76% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.16 | Revenue CAGR: 2.30% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.92 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+10.0% | GrowthRev=+5.0%
EPS next Year (2027-12-31): EPS=2.16 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+12.7% | GrowthRev=+6.6%
[Analyst] Revisions Ratio: +0% (up=2, down=2)